ABVC BioPharma, Inc. (ABVC)
NASDAQ: ABVC · Real-Time Price · USD
0.567
+0.042 (8.04%)
Nov 20, 2024, 4:00 PM EST - Market closed
ABVC BioPharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 0.51 | 0.15 | 0.97 | 0.36 | 0.48 | 0.7 | Upgrade
|
| Revenue Growth (YoY) | -31.04% | -84.28% | 172.57% | -26.34% | -31.16% | 9987.97% | Upgrade
|
| Cost of Revenue | 0.14 | 0.3 | 0.29 | 0.01 | 0.02 | 0.02 | Upgrade
|
| Gross Profit | 0.37 | -0.15 | 0.68 | 0.35 | 0.46 | 0.68 | Upgrade
|
| Selling, General & Admin | 3.3 | 5.37 | 6.07 | 5.75 | 4.27 | 3.07 | Upgrade
|
| Research & Development | 0.22 | 1.06 | 2.69 | 1 | 0.55 | 1.05 | Upgrade
|
| Operating Expenses | 6.66 | 8.07 | 15.8 | 12.06 | 8.97 | 4.14 | Upgrade
|
| Operating Income | -6.29 | -8.22 | -15.11 | -11.71 | -8.51 | -3.46 | Upgrade
|
| Interest Expense | -2.27 | -2.49 | -0.29 | -0.23 | -0.41 | -0.48 | Upgrade
|
| Interest & Investment Income | 0.11 | 0.19 | 0.19 | 0.04 | 0.07 | 0.02 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.1 | 0.02 | -0.26 | 0.43 | -0 | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.05 | 0.07 | 0.08 | 0.16 | 0.2 | 0.12 | Upgrade
|
| EBT Excluding Unusual Items | -8.43 | -10.43 | -15.4 | -11.3 | -8.64 | -3.8 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.22 | -0.22 | -0.01 | -0.27 | -2.17 | -0.21 | Upgrade
|
| Asset Writedown | - | - | -0.11 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 0.36 | - | - | Upgrade
|
| Pretax Income | -8.65 | -10.65 | -15.51 | -11.21 | -10.81 | -4.01 | Upgrade
|
| Income Tax Expense | 0.06 | 0.26 | 0.8 | 0.83 | -0.22 | -0.08 | Upgrade
|
| Earnings From Continuing Operations | -8.72 | -10.91 | -16.31 | -12.04 | -10.59 | -3.93 | Upgrade
|
| Minority Interest in Earnings | 0.47 | 0.39 | -0.11 | -0.8 | 0.8 | 0.29 | Upgrade
|
| Net Income | -8.24 | -10.52 | -16.42 | -12.84 | -9.79 | -3.64 | Upgrade
|
| Net Income to Common | -8.24 | -10.52 | -16.42 | -12.84 | -9.79 | -3.64 | Upgrade
|
| Shares Outstanding (Basic) | 10 | 4 | 3 | 3 | 2 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 10 | 4 | 3 | 3 | 2 | 2 | Upgrade
|
| Shares Change (YoY) | 187.47% | 36.92% | 26.39% | 27.07% | 12.67% | 47.26% | Upgrade
|
| EPS (Basic) | -0.82 | -2.43 | -5.19 | -5.12 | -4.97 | -2.08 | Upgrade
|
| EPS (Diluted) | -0.82 | -2.43 | -5.19 | -5.12 | -5.00 | -2.10 | Upgrade
|
| Free Cash Flow | -1.79 | -4.26 | -7.52 | -7.62 | -4.56 | -3.13 | Upgrade
|
| Free Cash Flow Per Share | -0.18 | -0.98 | -2.37 | -3.04 | -2.31 | -1.79 | Upgrade
|
| Gross Margin | 72.54% | -98.15% | 70.47% | 98.57% | 96.13% | 97.13% | Upgrade
|
| Operating Margin | -1233.06% | -5390.35% | -1558.54% | -3290.07% | -1760.87% | -492.90% | Upgrade
|
| Profit Margin | -1616.97% | -6898.68% | -1693.50% | -3608.47% | -2026.97% | -518.98% | Upgrade
|
| Free Cash Flow Margin | -352.11% | -2792.79% | -775.23% | -2140.33% | -944.82% | -446.69% | Upgrade
|
| EBITDA | -6.26 | -8.19 | -15.09 | -11.69 | -8.47 | -3.4 | Upgrade
|
| D&A For EBITDA | 0.03 | 0.03 | 0.02 | 0.01 | 0.04 | 0.06 | Upgrade
|
| EBIT | -6.29 | -8.22 | -15.11 | -11.71 | -8.51 | -3.46 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.